These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 23867513)

  • 1. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
    Harshman LC; Choueiri TK
    Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prospect of precision therapy for renal cell carcinoma.
    Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
    Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-clear cell advanced kidney cancer: is there a gold standard?
    Sánchez P; Calvo E; Durán I
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
    Salvi A; Marchina E; Benetti A; Grigolato P; De Petro G; Barlati S
    Int J Oncol; 2008 Aug; 33(2):271-6. PubMed ID: 18636147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
    Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
    Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of HGF and its receptor c-Met in renal cell carcinoma].
    Shi BB; Zhang XH; Wang HJ; Li HZ
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):356-8. PubMed ID: 15312347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.
    Golovine K; Makhov P; Naito S; Raiyani H; Tomaszewski J; Mehrazin R; Tulin A; Kutikov A; Uzzo RG; Kolenko VM
    Cancer Biol Ther; 2015; 16(5):743-9. PubMed ID: 25801713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma.
    Miyata Y; Kanetake H; Kanda S
    Clin Cancer Res; 2006 Aug; 12(16):4876-81. PubMed ID: 16914575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas.
    Oh RR; Park JY; Lee JH; Shin MS; Kim HS; Lee SK; Kim YS; Lee SH; Lee SN; Yang YM; Yoo NJ; Lee JY; Park WS
    APMIS; 2002 Mar; 110(3):229-38. PubMed ID: 12076276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.
    Schneider M; Schüler J; Höfflin R; Korzeniewski N; Grüllich C; Roth W; Teber D; Hadaschik B; Pahernik S; Hohenfellner M; Duensing S
    Urol Oncol; 2014 Aug; 32(6):877-84. PubMed ID: 24929890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
    Christensen JG; Burrows J; Salgia R
    Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.
    Macher-Goeppinger S; Keith M; Endris V; Penzel R; Tagscherer KE; Pahernik S; Hohenfellner M; Gardner H; Grüllich C; Schirmacher P; Roth W
    Oncotarget; 2017 Jan; 8(1):1046-1057. PubMed ID: 27894094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation.
    Nakamura T; Kanda S; Yamamoto K; Kohno T; Maeda K; Matsuyama T; Kanetake H
    Oncogene; 2001 Nov; 20(52):7610-23. PubMed ID: 11753639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth.
    Inoue K; Karashima T; Chikazawa M; Iiyama T; Yoshikawa C; Furihata M; Ohtsuki Y; Shuin T
    Virchows Arch; 1998 Dec; 433(6):511-5. PubMed ID: 9870683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
    Schmidt L; Duh FM; Chen F; Kishida T; Glenn G; Choyke P; Scherer SW; Zhuang Z; Lubensky I; Dean M; Allikmets R; Chidambaram A; Bergerheim UR; Feltis JT; Casadevall C; Zamarron A; Bernues M; Richard S; Lips CJ; Walther MM; Tsui LC; Geil L; Orcutt ML; Stackhouse T; Lipan J; Slife L; Brauch H; Decker J; Niehans G; Hughson MD; Moch H; Storkel S; Lerman MI; Linehan WM; Zbar B
    Nat Genet; 1997 May; 16(1):68-73. PubMed ID: 9140397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.
    Cai W; Rook SL; Jiang ZY; Takahara N; Aiello LP
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1885-93. PubMed ID: 10845613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
    Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
    Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.